ARAntoine Rostang

Antoine Rostang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antoine Rostang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A blinded, non-inferiority randomised clinical trial comparing the efficacy and safety of low-dose methotrexate and ciclosporin for the control of moderate to severe canine atopic dermatitis

    by Antoine Rostang, Marion Mosca, Pauline Panzuti, Charline Pressanti, Adrien Idée, Estelle Buendia, Pierre-Antoine Germain, Noëlle Cochet-Faivre, Lisa Meyer, Mélanie Legain, et al.

  • Open Access

    Susceptibility of Aeromonas salmonicida subsp. salmonicida bacteria from French farmed trout to antibiotics commonly used in fish farming, and attempt to set epidemiological cut-off values

    by Antoine Rostang, Florine Bachelet, Catherine Fournel, Titouan Carabin, Nora Navarro-Gonzalez, Ségolène Calvez

    Aeromonas salmonicida subsp. salmonicida (ASS) is a bacterium that can cause opportunistic infections in humans and animals. In farmed rainbow trout it causes furunculosis, with more frequent outbreaks when water temperatures are higher, an additional consequence of global warming. When infections occur, antibiotics are sometimes required. However, data on ASS susceptibility is limited. The aim of this study was to determine the distribution of Minimum Inhibitory Concentrations (MICs) of eight antibiotics commonly used in fish veterinary medicine in a population of pathogenic ASS, and to calculate provisional epidemiological cut-off values (called COEpid). To date, only four epidemiological cut-off values (ECV) have been established by CLSI, and none by EUCAST. In this study, 406 bacterial strains of ASS were collected exclusively from diseased French farmed trout over a 10-year period (2012–2021). A combination of PCR, MALDI-TOF and specific characteristics of the bacterial culture was used to identify each isolate to species level. All MIC data were obtained by the broth dilution method according to CLSI recommendations. Our COEpid meets the CLSI defined ECV for florfenicol (4 mg/L) and oxytetracycline (1 mg/L). In the absence of a defined ECV, we proposed a COEpid of 1 mg/L for doxycycline. For sulfadiazine alone, all strains tested were non-wild-type (NWT) with very high MICs. The COEpid was calculated as 4.8/0.25 mg/L for sulfadiazine + trimethoprim (one two-fold dilution difference from the ECV established by CLSI for ormetoprim + sulfadimethoxine). For quinolones, COEpid were 4 mg/L, 4 mg/L and 0.5 mg/L for oxolinic acid, flumequine and enrofloxacin, respectively, with a cross-resistance mechanism. This COEpid for oxolinic acid far exceeds the CLSI defined ECV (0.125 mg/L). A total of 12 strains (3%) were classified as NWT for all antibiotics tested. Over the period studied, the proportion of bacteria susceptible to the different molecules remained stable, except for the tetracycline family. These data will be available to establish internationally agreed epidemiological cut-off values, which are lacking for some antibiotics. These cut-offs are essential to assess and monitor the emergence of bacterial populations with resistance traits, and to establish clinical breakpoints for better use of antimicrobials in fish.


  • Open Access

    La pharmacie vétérinaire – un enjeu majeur pour un élevage durable

    by Antoine Rostang, Catherine Belloc, Mily Leblanc Maridor, Hervé Pouliquen

    Le médicament vétérinaire n’est pas un produit comme les autres. Ainsi, il ne peut être commercialisé qu’après obtention d’une Autorisation de Mise sur le Marché (AMM), fondée sur une évaluation scientifique stricte de sa qualité, de son efficacité, de son innocuité, et des résidus retrouvés dans les denrées alimentaires, par une autorité publique compétente. De même, sa commercialisation est très encadrée, avec un rôle central du vétérinaire de l’élevage, et une traçabilité rigoureuse qui assure une protection efficace du consommateur. La pharmacie vétérinaire est une composante clé de la gestion de la santé et du bien-être des animaux d’élevage. Bien utiliser le médicament reste indispensable pour un élevage plus durable. Ainsi, il faut réduire l’usage des anti-infectieux au strict nécessaire, dans un environnement de lutte contre la sélection et la diffusion de gènes de résistances. A contrario, le recours aux vaccins, aux anti-inflammatoires ou aux antidouleurs doit être absolument encouragé pour lutter contre les maladies infectieuses ou améliorer le bien-être animal. Parfois, à cause de l’écotoxicité de certains médicaments, ou de par l’existence de chartes et de labels spécifiques, de nouvelles stratégies doivent être mises en place pour la gestion de la santé des animaux. Dans tous ces domaines, même s’il reste encore beaucoup de connaissances nouvelles à produire, de pratiques à changer ou d’alternatives à mettre au point, l’élevage français a fait de grands progrès ces dernières années. Reste à communiquer auprès du grand public qui conserve une image très dégradée du médicament en élevage.


  • Open Access

    Evaluation of the efficacy of enrofloxacin in rainbow trout ( Oncorhynchus mykiss ) following experimental challenge with Yersinia ruckeri

    by Antoine Rostang, Carole Peroz, Catherine Fournel, Chantal Thorin, Ségolène Calvez

    Background: Use of enrofloxacin in trout farms is reported, especially for the treatment of yersiniosis, albeit various dosing regimens have been used. Therefore, optimal doses should be investigated. Methods: Five groups of 15 fish were challenged with Y. ruckeri . Two days later, three groups received feed containing enrofloxacin (ENR) at 1, 2.5 and 5 mg/kg fish respectively, during 7 days; one group received a single intraperitoneal injection of ENR at 10 mg/kg; and one group was left untreated. On day 15, surviving fish were euthanized. Results: All fish survived in the group treated by injection, compared to 53%, 60% and 40% of the fish treated with 1, 2.5 and 5 mg/kg oral ENR, respectively, and 53% in the infected untreated group. Conclusion: A single intraperitoneal injection of ENR at 10 mg/kg seems more relevant than repeated oral administrations. The ENR oral doses used in trout farms should be revised.


  • Pharmacokinetics of low-dose methotrexate in horses

    by Antoine Rostang, Isabelle Desjardins, Bernadette Espana, Pauline Panzuti, Philippe Berny, Caroline Prouillac, Didier Pin

    This study aimed to investigate both the pharmacokinetic behavior and tolerance of methotrexate (MTX) in horses to design a specific dosing regimen as a new immunomodulatory drug for long-term treatment. To determine the primary plasma pharmacokinetic variables after single intravenous, subcutaneous or oral administration, six horses were administered 0.3 mg/kg MTX in a crossover design study. After a 10-week washout, MTX was administered subcutaneously to three of the six previously treated horses at a dose of 0.3 mg/kg once per week for 3 months. In both studies, MTX and metabolite concentrations were measured using LC-MS/MS. The absolute bioavailability of MTX was 73% following subcutaneous administration but less than 1% following oral administration. The plasma clearance was 1.54 ml min(-1) kg(-1) (extraction ratio = 2%). After 24 hr, plasma concentrations were below the LOQ. No adverse effects were noted except for a moderate reversible elevation in liver enzymes (GLDH). With regards to the main metabolites of MTX, very low concentrations of 7-hydroxy-MTX were found, whereas polyglutamated forms (mainly short chains) were found in red blood cells. A subcutaneous dose of 0.2 mg kg(-1) week(-1) may be safe and relevant in horses, although this has yet to be clinically confirmed.


  • Pharmacokinetics of low‐dose methotrexate in healthy beagle dogs

    by Antoine Rostang, Marion Mosca, Morgan Jeannin, Coralie Luissiez, Philippe Berny, Isabelle Fourel, Didier Pin, Caroline Prouillac

    Methotrexate may be an alternative to ciclosporin in the treatment of canine atopic dermatitis (cAD) as suggested by recent data. The aim of the study was to investigate both the tolerance and the pharmacokinetic behavior of methotrexate (MTX) in plasma, following intravenous (i.v.), subcutaneous (s.c.) or oral (OR) administration over several weeks. Six healthy dogs were given oral MTX once a week, respectively, per dog at 2.5 mg/1 week, 5 mg/4 weeks, 7.5 mg/3 weeks, 10 mg/6 weeks and 12.5 mg/5 weeks. No clinically relevant abnormalities of laboratory parameters were noticed. A high inter‐individual variation of MTX plasma concentration was observed with a suspicion of saturation phenomenon in absorption. To compare with other routes of administration, six healthy beagle dogs followed a crossover design study at 7.5 mg per dog MTX. The absolute bioavailability was 93% for SC injection and 30% for the oral route. The inter‐individual variability was quite low following SC administration compared to oral route. Just as in human, given the substantial variability of oral absorption, clinicians cannot assume consistent oral bioavailability of MTX. Therefore, they may consider switching dogs to the SC route in case of absence of clinical response with a weekly oral dose.